ALL
Conference Coverage
Phase 3 results: Ponatinib bests imatinib for Ph+ALL
First prospective study of third-generation TKI ponatinib showed its comparative benefit for the most common subtype of adult ALL.
Commentary
75 years: A look back on the fascinating history of methotrexate and folate antagonists
Dr. David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate’s...
Feature
Mastocytosis: Rare, underdiagnosed, potentially fatal
This often-missed myeloid neoplasm could be deadly and deserves greater attention, experts say.
Feature
MD-researcher keeps her eyes on the prize
Researching CAR T-cell therapies for T-ALL, a physician-scientist works to saves children’s lives, as hers was saved.
Conference Coverage
Immunotherapy drug boosts survival in newly diagnosed ALL
First-line treatment with expensive medication should become standard, researcher says.
Conference Coverage
‘Clear answer’: ALL study defies conventional wisdom
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
From the Journals
Novel co-admin of CAR T cells achieves 99% remission in leukemia
“We do believe [this approach] will become standard of care.”
Feature
Worldwide trial seeks to revolutionize pediatric leukemia care
Leukemia & Lymphoma Society project offers free genomic screening, plus access to subtrials.
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.